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Abstract
Background: Individuals with type 2 diabetes mellitus (T2DM) have elevated levels of circulating
apolipoprotein CIII (apoCIII). ApoCIII plays an important role for plasma triglyceride levels and
elevated levels of the apolipoprotein have been connected with dyslipidemia in T2DM subjects. In
addition, apoCIII has been linked to enhanced β-cell apoptosis. The present study was undertaken
to investigate apoptotic mechanisms induced by the apolipoprotein.
Results: ApoCIII (10 μg/ml) enhanced apoptosis 2-fold in insulin-producing INS-1E cells after 24
hours exposure to the apolipoprotein. At this time point phosphorylation of mitogen activated
protein kinase (MAPK) p38 had doubled but ERK1/2 and JNK were not activated. Instead, ERK1/2
showed rapid and transient phosphorylation (2-fold after 0.5 hour). No JNK phosphorylation was
observed. In support of a role of activation of not only p38 but also ERK1/2 in apoCIII-induced
apoptosis, inclusion of p38 inhibitor SB203580 (10 μM) or ERK1/2 inhibitor PD98059 (100 μM)
normalized apoptosis. Whereas influx of Ca2+ was linked to apoCIII-induced ERK1/2 activation,
pro-apoptotic protein CHOP/GADD of the unfolded protein response (UPR) was not affected by
apoCIII.
Conclusion:  It is suggested that elevated circulating apoCIII levels may contribute to β-cell
apoptosis via activation of p38 and ERK1/2 in individuals with T2DM. Therapies aiming at
normalizing levels of apoCIII could be beneficial not only for the function of the β-cell but also for
cardiovascular protection.
Background
Type 2 diabetes mellitus (T2DM) is a disease involving
both genetic and environmental factors [1,2] resulting in
elevated circulating levels of glucose and lipids [3]. The
negative effects of these elevated nutrient levels on β-cell
function and mass are well documented [4-7]. Although
causes of both genetic and environmental origin have
been linked to these disturbances, the mechanisms
remain to a great extent undefined, which is at least partly
due to the complexity of T2DM. To dissect the multifacto-
rial etiology of the disease studies have been undertaken,
where analysis of changes in circulating levels of multiple
proteins has been conducted by proteomic methodology
[8-10]. In one of the studies the aim was to identify differ-
entially displayed circulating proteins in individuals with
T2DM potentially contributing to development of
impaired β-cell function [9]. The experimental approach
stems from work, where alterations in levels of circulating
proteins, e.g. gut hormones and cytokines, have been
demonstrated to have effects on β-cell function and mass
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[11,12]. To this aim serum samples from subjects with
newly diagnosed diabetes with family history of diabetes
(FHD) and impaired β-cell function, and from healthy
individuals with no FHD and well functioning β-cells
were protein profiled. Several circulating proteins were
differentially displayed in the newly diagnosed T2DM
individuals [9]. In the present study we have investigated
mechanisms by which one of the identified proteins,
apolipoprotein CIII (apoCIII), affects the insulin-produc-
ing cell. The choice of protein was based on the observed
up-regulation of apoCIII in the circulation in individuals
with T2DM [9,13,14] and enhanced apoptosis in an insu-
lin-secreting cell line exposed to the apolipoprotein [15].
In the present study we hypothesized that apoCIII-
induced β-cell apoptosis was connected to activation of
mitogen-activated protein kinases (MAPKs) and/or induc-
tion of the pro-apoptotic protein CCAAT/enhancer-bind-
ing protein homologous protein/growth arrest and DNA-
damage 153 (CHOP/GADD153) of the unfolded protein
response (UPR), mechanisms which have been demon-
strated to be activated in β-cell apoptosis [7,16-19]. The
results indicate that MAPKs p38 and extracellular signal-
regulated protein kinases 1 and 2 (ERK1/2), but not c-Jun
NH2-terminal kinase (JNK) or CHOP/GADD153 play a
role in apoCIII-induced β-cell apoptosis.
Methods
Chemicals and reagents
Reagents of analytical grade and MilliQ water were used.
ApoCIII was purchased from Meridian Life Science (Saco,
MA). PD98059, SB203580, verapamil, tolbutamide, thap-
sigargin and protease inhibitory cocktail (Sigma P-8340)
were obtained from Sigma (St. Louis, MO). RPMI 1640
culture medium, fetal calf serum (FCS), sodium pyruvate,
glutamine, penicillin and streptomycin were purchased
from Invitrogen (Carlsbad, CA). Culture flasks and plates
were from BD Biosciences Labware (Franklin Lakes, NJ).
Cell culture
Rat insulinoma INS-1E cells, supplied by Dr. P Maechler,
Geneva University, Switzerland [20], were cultured in a
humidified atmosphere containing 5% CO2  in RPMI
1640 medium supplemented with 10 mM HEPES, 10%
(v/v) heat-inactivated FCS, 2 mM glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, 1 mM sodium pyru-
vate and 50 μM β-mercaptoethanol. Sub-confluent INS-
1E cells were exposed to 10 μg/ml apoCIII for 24 hours. In
addition, PD98059 (100 μM) or SB203580 (10 μM) was
included into the culture medium 0.5 hour prior to intro-
ducing apoCIII. Verapamil (100 μM) was added to INS-1E
cells for 5 minutes and then withdrawn before exposing
the cells to apoCIII. Tolbutamide (1 mM) was added into
the medium and present throughout the culture period.
As positive control for CHOP/GADD153, 300 nM thapsi-
gargin was added to the culture medium and was present
during the whole culture period. The positive control for
the different MAPKs were obtained by exposing the cells
for 10 minutes at 5 mW/cm2 of UV-irridation (Emax = 310
nM) with a transilluminator (San Gabriel, CA), followed
by additional 10 minutes in the incubator before sample
preparation.
Protein measurements
Protein extracts were prepared by lysis of INS-1E cells with
a buffer composed of 150 mM NaCl, 50 mM Trizmabase,
1% Triton X100, 0.25% Na-deoxycholate, 1 mM Na3VO4,
2 mM EGTA and a protease inhibitory cocktail. Extracts
were subjected to SDS-PAGE, transferred to PVDF-mem-
brane and immunoblotted. Antibodies against phosphor-
ylated and un-phosphorylated p38, ERK1/2 and JNK were
obtained from Cell Signaling (Beverly, MA). The CHOP/
GADD153 and β-actin antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). The
immuno-reactive bands were visualized by chemilumi-
nescence ('ECL Plus' or 'ECL Advance', GE Healthcare,
Uppsala, Sweden) according to the manufacturer's proto-
col, imaged with Fluor-S MultiImager MAX (Bio-Rad, Her-
cules, CA). After imaging, the PVDF membranes were
quantified with Quantity One software (BioRad). The
expression level of each protein was normalized to un-
phosphorylated MAPK and/or β-actin.
Apoptosis measurements
DNA fragmentation of INS-1E cells was evaluated by
determining oligonucleosome formation using the Cell
Death Detection ELISAPLUS kit (Roche Diagnostics, Man-
nheim, Germany). Measurements were related to DNA
content and expressed as fold of optical density obtained
for control cells cultured in the absence of apoCIII.
Statistical analysis
Results are presented as means ± SEM (apoptosis) or rep-
resentative blots (MAPKs and CHOP/GADD153) for four
independent experiments. Western blots were densito-
metrically analyzed. Differences between groups are
assessed by ANOVA followed by Tukey's post hoc test for
apoptosis measurements and Student's t-test for immuno-
blots. A probability level of p < 0.05 was considered to be
statistically significant.
Results
ApoCIII-induced apoptosis and MAPKs
Apoptosis was increased by 2-fold when INS-1E cells were
exposed to apoCIII for 24 hours (Fig 1). To investigate
underlying mechanisms of the apoCIII-induced rise in
apoptosis, activation of MAPKs p38, ERK1/2 and JNK in
INS-1E cells were measured at 0, 0.5, 1, 2, 4, 8, 12 and 24
hours after introduction of the apolipoprotein. Levels of
p-p38 were low in the cells at onset of the apoCIII-expo-
sure and were then progressively increasing for the dura-Lipids in Health and Disease 2009, 8:3 http://www.lipidworld.com/content/8/1/3
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tion of the experiment manifested as 2-fold rise (p < 0.05)
after 24 hours (Fig 2A). To determine if activation of the
MAPK was causually related to apoCIII-induced apopto-
sis, cells were exposed to the inhibitor of p38 phosphor-
ylation SB203580 prior to introducing apoCIII.
Administration of the inhibitor normalized p-p38 levels
(not shown), which was accompanied by reduction of
apoptosis to control levels in apoCIII-exposed cells (Fig
1). The inhibitor alone had no effect on apoptosis.
Involvement of ERK1/2 in apoCIII-induced apoptosis in
INS-1E cells was also investigated. Levels of p-ERK1/2
were elevated 2-fold (p < 0.05) already after 0.5 hour and
declined thereafter (Fig 2B). After 24 hours, when the
apoCIII-induced rise in apoptosis was determined, ERK1/
2 levels had returned to control levels. To investigate
whether the early rise in p-ERK1/2 was contributing to
apoCIII-induced apoptosis, cells were exposed to the
inhibitor of ERK1/2 phosphorylation PD98059 prior to
introducing apoCIII. Pre-exposing the cells to the inhibi-
tor prevented the apoCIII-induced rise in p-ERK1/2 (not
shown) and reversed apoptosis in the presence of the
apolipoprotein (Fig 1). The inhibitor alone had no effect
on apoptosis. Thirdly, phosphorylation of JNK was meas-
ured in INS-1E cells exposed to apoCIII. No activation of
the MAPK by the apolipoprotein was observed during the
24-hour exposure time (Fig 2C).
ApoCIII-induced ERK1/2 activation and calcium
The role of Ca2+ influx for ERK1/2 activation was next
investigated. INS-1E cells treated with apoCIII were
exposed to L-type Ca2+ channel blocker verapamil prior to
apoCIII-treatment. ApoCIII-induced ERK1/2 activation
observed after 0.5 hour was reversed by treatment with the
channel antagonist (Fig 3). Further support of a role of
Ca2+ influx as activator of ERK1/2 was provided when INS-
1E cells were exposed to tolbutamide. After treatment
with the KATP channel blocker, elevated levels (p < 0.05) of
p-ERK1/2 were observed (Fig 3).
ApoCIII-induced apoptosis and CHOP
Lastly, we investigated if apoCIII-induced elevated apop-
tosis in INS-1E cells (Fig 1) involved enhanced expression
of pro-apoptotic protein CHOP/GADD153. In the
apoCIII-exposed cells CHOP/GADD153 protein levels
ApoCIII-induced apoptosis Figure 1
ApoCIII-induced apoptosis. INS-1E cells were cultured 
for 24 hours in the absence or presence of 10 μg/ml apoCIII. 
Cells were exposed to 10 μM of the p38 inhibitor SB203580 
(SB) or 100 μM of the ERK1/2 inhibitor PD98059 (PD) dur-
ing 0.5 hours prior to apoCIII treatment as indicated. After 
culture, apoptosis was measured as DNA fragmentation and 
normalized to DNA content. *P < 0.05 denotes effect of 
apoCIII.
ApoCIII-induced MAPK-activation Figure 2
ApoCIII-induced MAPK-activation. Levels of phosphor-
ylated p38 (A), ERK1/2 (B) and JNK (C) in apoCIII-treated 
INS-1E cells were measured at the indicated time points. 
Cells exposed to ultraviolet light (UV) were used as positive 
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were not different from those observed under control con-
ditions, however (Fig 4).
Discussion
The present study indicates that elevated levels of the
apolipoprotein apoCIII could promote apoptosis in insu-
lin-producing  β-cells via activation of MAPK p38 and
ERK1/2. The study is a continuation of our previous study
in which apoCIII was identified as an up-regulated pro-
tein by proteomic methodology when serum obtained
from individuals with newly diagnosed T2DM and docu-
mented impaired β-cell function was compared to serum
from control individuals with normal β-cell function [9].
ApoCIII is an 8.8 kDa polypeptide synthesized by the liver
and playing an important role in controlling catabolism
of triglyceride-rich lipoproteins by inhibiting the activity
of lipoprotein lipase thereby inducing hypertriglyceri-
demia [21,22]. The apolipoprotein is mainly associated
with HDL but also with LDL and VLDL [23,24]. In indi-
viduals with T2DM the levels of the apolipoprotein is ele-
vated [9,13,14]. To what extent the elevated apoCIII levels
in T2DM are accounted for by rise in a particular lipopro-
tein particle class is less clear, however. Although the lev-
els of VLDL in T2DM individuals are increased
substantially compared to non-diabetic subjects, apoCIII
was not increasing in concert with the increased VLDL
concentration and core lipids in these individuals [14].
Instead increased apoCIII content was observed in small
dense LDL (sdLDL) in T2DM patients compared to the
corresponding fraction from healthy individuals [25]. The
potential role of the sdLDL, which is a lipoprotein sub-
class, was further emphasized by the strong association
with coronary disease progression. Based on these results
sdLDL and apoCIII have been suggested as markers of the
atherogenic dyslipidemia of insulin resistance and type 2
diabetes [25-27]. In addition, connection between genetic
alterations in apoCIII and T2DM was recently evidenced
by the finding of strong association between changes in
ApoC3 with lipid derangements in individuals with the
disease [28]. When over-expressing apoCIII in transgenic
mice, hypertriglyceridemia follows [29]. Conversely, dis-
ruption of ApoC3 in mice reduced triglyceride levels [30].
Despite the strong correlation relationship between
apoCIII and triglyceride levels [13], very little is known
about direct effects of the apolipoprotein on the insulin-
producing cell.
Elevated apoCIII levels have in one previous study been
associated with enhanced apoptosis in insulin-secreting β-
cells possibly explained by elevated cytoplasmic Ca2+ lev-
els [15]. Since disturbed Ca2+ homeostasis of the endo-
plasmic reticulum (ER) would be manifested as elevated
cytoplasmic Ca2+ levels, we examined if apoCIII-induced
apoptosis was connected to up-regulation of the pro-
apoptotic protein CHOP/GADD153. The protein is a
down-stream target of the protein kinase R-like ER kinase
(PERK) signaling pathway of the ER-stress response [31].
The pathway is part of an adaptive response, the unfolded
protein response (UPR), aiming at restoring ER function
when mis- or unfolded proteins accumulate in the
organelle as a consequence of disturbances in ER Ca2+.
When the UPR fails, persisting ER-stress follows and
apoptosis is elevated, where up-regulation of CHOP/
GADD153 is a component part [7,19]. The enhanced
apoptosis induced by apoCIII in INS-1E cells in the
present study was not associated with enhanced CHOP/
GADD153 levels, however.
We also investigated to what extent apoCIII activated
MAPKs p38, JNK and ERK1/2. Treating INS-1E cells with
apoCIII almost doubled the amounts of p-p38 after 24
hours exposure to the apolipoprotein. A role of this acti-
vation in apoCIII-induced apoptosis was supported by the
abrogation of apoptosis when inhibitor of the kinase was
administered. In addition, activation of the MAPK has
been observed in β-cells exposed to elevated levels of fatty
acids, oxygen radical formation and cytokine, all condi-
tions connected with enhanced β-cell apoptosis [16,17].
ERK1/2 activation was also induced by apoCIII but with a
more rapid and transient phosphorylation pattern. Our
observations that administration of the L-type Ca2+ chan-
nel antagonist verapamil abrogated rise in p-ERK1/2
induced by apoCIII and that KATP channel blocker tolbuta-
mide induced ERK1/2 activation are supporting a role of
Ca2+ influx, induced by apoCIII, as a component of the
ERK1/2 activation [15,32]. ERK1/2 activation does not
seem to be essential for the short-term performance of the
β-cell since glucose-stimulated insulin secretion (GSIS)
ApoCIII-induced ERK1/2 activation Figure 3
ApoCIII-induced ERK1/2 activation. Levels of phosphor-
ylated ERK1/2 in INS-1E cells treated or not with apoCIII 
were measured after 0.5 hours by immunoblotting. Cells 
were exposed to L-type Ca2+ channel blocker verapamil 
(Verap) or KATP channel blocker tolbutamide (Tolb) as indi-
cated.Lipids in Health and Disease 2009, 8:3 http://www.lipidworld.com/content/8/1/3
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was not affected by presence of an inhibitor of the kinases
[32]. In contrast, when the inhibitor was administered to
islets exposed to prolonged elevated glucose levels, which
in the absence of the inhibitor caused similar rapid and
transient ERK1/2 activation and was associated with
impaired glucose-stimulated insulin secretion and apop-
tosis, improved GSIS and reduced apoptosis was observed
[18]. The same beneficial effects were obtained by L-type
Ca2+ channel antagonist nimodipine. Thus, apoCIII ele-
vates cytoplasmic Ca2+ levels by promoting Ca2+ influx.
Although such influx promotes insulin secretion in the
short perspective, prolonged elevated Ca2+ levels are asso-
ciated with enhanced β-cell apoptosis [15,33]. Among the
pro-apoptotic signaling pathways ERK1/2 and p38 activa-
tion seem to play fundamental roles since their inhibi-
tions, without Ca2+  antagonism, independently
normalized apoCIII-induced apoptosis. In contrast, JNK
was not activated by apoCIII.
Conclusion
In conclusion, the study indicates that elevated levels of
the apolipoprotein apoCIII may affect β-cell function via
activation of MAPKs p38 and ERK1/2. In addition, nega-
tive effects of apoCIII on β-cell function may also be medi-
ated by the rise in circulating triglycerides associated with
elevated levels of the apolipoprotein [13,22,34]. In this
perspective, therapies aiming at normalizing levels of
apoCIII including benzafibrate could prove to be impor-
tant not only for cardiovascular protection [26] but also to
preserve β-cell function.
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